{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["177Lu-DOTA-TLX591"]],"indication":"PSMA-expressing metastatic castration-resistant prostate cancer","name":"ProstACT SELECT","nct_id":"NCT04786847","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prostact-select-nct04786847. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ProstACTSelect","arms":[{"description":"Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart. This therapy will be administered with the current standard of care treatment regimens.","label":"Single administration of 177Lu-DOTA-TLX591","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-09-30","type":"ACTUAL"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":30,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"177Lu-DOTA-TLX591","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2024-02-12","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","official_title":"A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0","timeFrame":"Day 1 to 5 years"}],"references":[],"start_date":{"date":"2022-01-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study","url":"https://clinicaltrials.gov/study/NCT04786847"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prostact-select-nct04786847"}